PORCH: Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer

Sponsor
UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT01776138
Collaborator
(none)
103
1
109.3
0.9

Study Details

Study Description

Brief Summary

The purpose of this study is to create a registry of older patients undergoing surgical and/or medical treatment for bladder cancer. The registry will record side-effect and outcomes related to the treatment using different surveys and biological measures.

Condition or Disease Intervention/Treatment Phase
  • Other: Collect Blood and Survey Instruments

Detailed Description

The primary purpose of this protocol is to create a registry of elderly patients with high-risk invasive bladder cancer undergoing radical cystectomy with or without preoperative chemotherapy.

Secondary objectives will include an exploration of the association between functional status, surgical complications, and laboratory markers with complications and survival. In addition, exploratory analyses may evaluate the association of expression of the senescence marker p16INK4a and the morbidity and mortality associated with treatment.

Patients will be asked to complete a Geriatric Assessment (GA) and FACT-Bl serially over the course of the study in order to evaluate their functional status and quality of life during the course of treatment. Additionally, complications will be tracked in an inpatient and outpatient setting using the Memorial Sloan Kettering Cancer Center (MSKCC) complications grading system.

Study Design

Study Type:
Observational
Actual Enrollment :
103 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy
Actual Study Start Date :
Jul 23, 2012
Actual Primary Completion Date :
Aug 29, 2019
Actual Study Completion Date :
Sep 2, 2021

Arms and Interventions

Arm Intervention/Treatment
Bladder Cancer Patients

Patients diagnoses with bladder cancer who are eligible to undergo treatment.

Other: Collect Blood and Survey Instruments
Other Names:
  • p16 Blood Collection
  • Geriatric Assessment
  • Fact-BL
  • Health Behavior Questionnaire
  • Outcome Measures

    Primary Outcome Measures

    1. To collect the number of changes in functional status, surgical complications and survival status collected in a prospective database of patients undergoing a radical cystectomy with or without chemotherapy [1 Year]

      To collect the number of changes in functional status, surgical complications, and survival in patients with urothelial carcinoma of the bladder following radical cystectomy with or without neoadjuvant chemotherapy in a prospective database (to be called the PORCH database- "Prospective Outcomes of Radical cystectomy with or without Chemotherapy").

    Secondary Outcome Measures

    1. To measure associations between baseline measures with post-surgery and 90 day outcome measures [2 years]

      Measure the association of all baseline measures with the outcomes of complications post-surgery and 90 day mortality for the 25 patients entered into the database who complete the GA and FACT-Bl questionnaires.

    2. To count changes over the course of treatment for components of the GA, the FACT-Bl, p16, and other clinical characteristics. [2 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with a known pathologic diagnosis of lower tract urothelial carcinoma who are eligible to undergo radical cystectomy with or without neoadjuvant chemotherapy for definitive diagnosis and treatment.

    • Signed, IRB approved written informed consent.

    • Completion of baseline Geriatric Assessment

    Exclusion Criteria:
    • Inability to read and speak English

    • Inability to comply with study for any other reason than language

    • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina United States 27514

    Sponsors and Collaborators

    • UNC Lineberger Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Angela Smith, MD, University of North Carolina Lineberger Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    UNC Lineberger Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT01776138
    Other Study ID Numbers:
    • LCCC1206
    • 12-0577
    First Posted:
    Jan 25, 2013
    Last Update Posted:
    Oct 6, 2021
    Last Verified:
    Oct 1, 2021
    Keywords provided by UNC Lineberger Comprehensive Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2021